ACRV
Acrivon Therapeutics, Inc. Common StockHealthcare·Biotechnology
$1.60
$50M market cap
Revenue
$0.0M
Free Cash Flow
$-36.0M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit fro
2-Year Price History
$1.75-75.9%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -19.5 | -19.9 | -19.0 | -20.5 | -20.6 | -0.0 | 97.7 | 2.4 | 38.7 | -371.8% | -- | -- |
| Act | 2025-Q4 | 0.0 | -26.1 | -20.1 | -19.0 | -15.2 | -15.5 | -0.2 | 118.6 | 2.7 | 38.5 | -204.9% | -- | -- |
Valuation & Metrics
Market Stats
Price$1.60
Market Cap$50M
Enterprise Value$-45M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-71.3%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-38.0M
Free Cash Flow$-36.0M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-288.3%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares2.5M
Days to Cover2.3
Change (vs Prior)+3.2%
Need at least 2 settlement dates for chart
Employees
Headcount75
Revenue / Employee$0
Gross Profit / Employee$7,040
Cash Runway
32.6months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
35.0%(-35.9% YoY)
32 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
3.4%(-4.7% YoY)
8 filers
Vanguard, iShares, SPDR
Market makers
0.6%(+0.6% YoY)
3 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $11.6M | $9.10 | +$0 | +$0 | -4.3% | $9.44B |
| Sands Capital Alternatives, LLC | $3.0M | $10.25 | +$0 | +$0 | -2.7% | $421M |
| WELLINGTON MANAGEMENT GROUP LLP | $1.2M | $11.52 | +$0 | +$0 | -0.3% | $533.98B |
| ACADIAN ASSET MANAGEMENT LLC | $1.2M | $2.03 | +$368K | +$1.2M | -0.5% | $70.48B |
| RENAISSANCE TECHNOLOGIES LLC | $1.1M | $2.10 | +$173K | +$982K | +1.2% | $63.91B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $1.0M | $1.39 | +$1.0M | +$1.0M | — | $4.04T |
| MARSHALL WACE, LLP | $779K | $8.59 | +$89K | +$153K | +0.6% | $92.71B |
| TWO SIGMA INVESTMENTS, LP | $541K | $2.27 | −$272K | +$541K | -0.9% | $117.03B |
| JANE STREET GROUP, LLCMM | $333K | $1.76 | −$142K | +$333K | -0.1% | $92.10B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $329K | $8.46 | +$53K | −$97K | +2.3% | $1.61T |
| BlackRock, Inc.Passive | $290K | $6.81 | +$5K | −$1.0M | -0.2% | $5.69T |
| GSA CAPITAL PARTNERS LLP | $260K | $1.39 | +$260K | +$260K | -5.9% | $1.61B |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $221K | $3.20 | +$161K | +$113K | -2.3% | $4.93B |
| VANGUARD FIDUCIARY TRUST COPassive | $149K | $1.39 | +$149K | +$149K | — | $395.83B |
| STATE STREET CORPPassive | $93K | $9.88 | +$0 | −$230K | -0.2% | $2.89T |
| XTX Topco Ltd | $93K | $1.57 | +$64K | +$93K | -1.9% | $5.74B |
| NORTHERN TRUST CORPPassive | $68K | $8.87 | −$21K | −$84K | -0.2% | $755.34B |
| MORGAN STANLEY | $51K | $4.91 | −$14K | +$2K | -0.3% | $1.65T |
| UBS Group AG | $48K | $2.10 | −$436K | +$30K | -0.3% | $562.11B |
| PANAGORA ASSET MANAGEMENT INC | $47K | $1.39 | +$47K | +$47K | +0.0% | $26.69B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-3.07%
avg per quarter
Holders (ex-self)
-2.95%
excl. this stock
Buyers (this Q)
-3.99%
12 buyers · $0.00B in
Sellers (this Q)
-0.43%
11 sellers · $0.00B out
alpha coverage: 95% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+10.8%
how holders react when this stock falls
On quiet Qs
-22.5%
−10% to +10% baseline
On rallies (+10%+)
+12.4%
how they react when this stock rises
Holders' portfolio flow this Q
+4.6%
inflows — adds are organic
Sellers' portfolio flow this Q
+34.0%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-1.4%
Holder mid (any stock)
-3.9%
Holder rally (any stock)
-1.5%
Biggest decreases this quarter
CITADEL ADVISORS LLCexited−$4.0MACORN CAPITAL ADVISORS, LLCexited−$977KUBS Group AG−$436Kα-0.3MILLENNIUM MANAGEMENT LLCexited−$293KTWO SIGMA INVESTMENTS, LP−$272Kα-0.9JANE STREET GROUP, LLC−$142Kα-0.1BAKER BROS. ADVISORS LPexited−$55KQuadrature Capital Ltdexited−$50KVermillion & White Wealth Management Group, LLCexited−$44KSchonfeld Strategic Advisors LLCexited−$40K
New buyers this quarter
Top-5 holders · 79.8%
RA CAPITAL MANAGEMENT, L.P.--
Sands Capital Alternatives, LLC--
WELLINGTON MANAGEMENT GROUP LLP--
ACADIAN ASSET MANAGEMENT LLC--
RENAISSANCE TECHNOLOGIES LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
RA CAPITAL MANAGEMENT, L.P.8.3MPERCEPTIVE ADVISORS LLC—Sands Capital Alternatives, LLC2.1MCITADEL ADVISORS LLC—MARSHALL WACE, LLP560KWELLINGTON MANAGEMENT GROUP LLP888KFEDERATED HERMES, INC.8KNEA Management Company, LLC—Paradigm Biocapital Advisors LP—HealthCor Management, L.P.—
Analyst Coverage
Analyst Coverage
Analyst Ratings
9
1
Buy: 9Hold: 1Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$114K
3 txns · 3 insiders · 67,832 sh
Sells ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-01-14 | BUY | Blume-Jensen Peter | director, officer: President and CEO | 49,000 | $1.68 | $82K | $3.51M |
| 2026-01-14 | BUY | Levy Adam D. | officer: Chief Financial Officer | 8,832 | $1.70 | $15K | $36K |
| 2026-01-13 | BUY | Devroe Eric | officer: Chief Operating Officer | 10,000 | $1.72 | $17K | $130K |
Order Flow (FINRA, ~3w lag)
42.9%retail-4.2pp
8.7%dark-1.5pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Acrivon Therapeutics, Inc.: The Dilution Engine Behind Precision Oncology
Overall Risk
7/10
Fraud
2/10
Dilution
9/10
Insolvency
4/10
Earnings Overstated
2/10
Hidden Liabilities
5/10
Legal
2/10
Audit Warnings
3/10
Hidden Upside
6/10
Contextually Acceptable
8/10